Cardiovascular (CV) complications are the most frequent cause of morbidity and mortality in autosomal dominant polycystic kidney disease (ADPKD) patients. In 2017, the Italian Medicines Agency authorised tolvaptan, a vasopressin V2 receptor antagonist, for the treatment of ADPKD, based on the Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD (TEMPO 3: 4), TEMPO 4: 4 and Replicating Evidence of Preserved Renal Function: An Investigation of Tolvaptan Safety and Efficacy (REPRISE) studies.
Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients in therapy with tolvaptan: A pilot study / Lai, Silvia; Mangiulli, Marco; Perrotta, Adolfo M; Gigante, Antonietta; Napoleoni, Ludovica; Cipolloni, Elena; Mitterhofer, Anna P; Gasperini, Maria L; Muscaritoli, Maurizio; Cianci, Rosario; Giovannetti, Antonello; Falco, Fabiana; Mastroluca, Daniela; Mazzaferro, Sandro. - In: CURRENT VASCULAR PHARMACOLOGY. - ISSN 1570-1611. - 18:(2020). [10.2174/1570161118999200918094809]
Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients in therapy with tolvaptan: A pilot study
Lai, Silvia;Gigante, Antonietta;Mitterhofer, Anna P;Muscaritoli, Maurizio;Cianci, Rosario;Giovannetti, Antonello;Mazzaferro, Sandro
2020
Abstract
Cardiovascular (CV) complications are the most frequent cause of morbidity and mortality in autosomal dominant polycystic kidney disease (ADPKD) patients. In 2017, the Italian Medicines Agency authorised tolvaptan, a vasopressin V2 receptor antagonist, for the treatment of ADPKD, based on the Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD (TEMPO 3: 4), TEMPO 4: 4 and Replicating Evidence of Preserved Renal Function: An Investigation of Tolvaptan Safety and Efficacy (REPRISE) studies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
